Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder

This study has been completed.
Sponsor:
Information provided by:
Targacept Inc.
ClinicalTrials.gov Identifier:
NCT00593879
First received: December 19, 2007
Last updated: January 2, 2008
Last verified: January 2008

December 19, 2007
January 2, 2008
February 2005
Not Provided
HAMD-17 group mean change from baseline to endpoint and/or the proportion of subjects considered to be full responders or in remission with a HAMD-17 score less than or equal to 7 at the end of treatment. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00593879 on ClinicalTrials.gov Archive Site
  • Montgomery Asbery depression rating sclae, Clinical Global Impression Scale - Severity, Clinical Global Impression Sacle - Change, Sheehan irritability scale, Sheehan disability scale [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Blood biochemistry, urnie analysis, blood pressure, heart rate, ECG [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  • Citalopram plasma bloods at week 6 and 14. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of Mecamylamine 5.0 to 10 mg, in the Treatment of Major Depressive Disorder With Subjects Who Are Partial or Non- Responders to Citalopram Therapy.

Depressed patients will receive 6 weeks of citaloprma (20-40mg) therapy. Subjects who have an inadequate response (partial or non-responder) will be randomized to receive either mecamylamine (5-10mg) or placebo added to their citalopram for a further 8 weeks.

This is a double blind, randomized, placebo controlled, parallel group, flexible dose titration, add-on study. Male or female subjects aged 18-70 years suffering from Major Depressive Disorder according to DSM-IV, with a HAMD-17 score greater than 21 and a CGI-Severity of Illness score greater or equal to 4, will be started on open labeled citalopram treatment. The dose of citalopram may be increased form 20mg to 40mg over a six week period, depending on investigator assessment of tolerability and efficacy. At the end of this treatment, subjects with a HAMD-17 score greater or equal to 14 and a CGI-Severity of Illness score greater or equal to 4 will be considered as partial or non-responders and will be entered into the double blind phase of the study. Subjects will be randomized to either mecamylamine or placebo for a further 8 weeks. Citalopram medication will remain constant while mecamylamine (or placebo) can be increased from 5.0 to 7.5 to 10.0mg based on investigator assessment of tolerability and efficacy.

Plasma samples for citalopram assay will be collected at the start and end of the double blind phase to exclude any mecamylamine effect being due to a drug:drug interaction.

Approximately 500 subjects will be entered into the open-label phase of the study and approximately 160 into the double blind phase. The study will be conducted in India and the USA.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Major Depressive Disorder
Drug: Mecamylamine
2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
Other Name: Inversine
  • Placebo Comparator: 1
    Placebo
    Intervention: Drug: Mecamylamine
  • Experimental: 2
    Intervention: Drug: Mecamylamine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
450
August 2006
Not Provided

Inclusion Criteria:

(A) Open Phase

  • Male or female subjects aged 18-70 years.
  • Diagnosis of major depressive disorder (MDD) according to DSM-IV and confirmed via MINI diagnostic scale.
  • Able to give written informed consent.
  • HAMD-17 score greater than 21.
  • CGI-Severity of Illness score greater than or equal to 4.
  • No clinically significant abnormality on physical examination, vital signs, ECG or laboratory tests (biochemical, hematological, urinary) at screening.
  • Women of child bearing potential with a negative urine pregnancy test and willing to use acceptable methods of contraception.

(B)Double Blind Phase:

  • Subjects still to meet DSM-IV criteria for MDD.
  • Subjects continue to meet all of the inclusion and exclusion criteria.
  • HAMD-17 score greater than or equal to 14.
  • CGI severity of illness score greater than or equal to 4.
  • Women of child bearing potential with a negative urine pregnancy test and willing to use acceptable methods of contraception.

Exclusion Criteria:

  • Aged below 18 years and above 70 years.
  • Failure to meet DSM IV criteria for MDD.
  • HAMD-17 less than or equal to 21 (open-label phase only).
  • CGI Severity of Illness score less than 4.
  • Clinically significant changes in physical examination, vital signs, ECG or laboratory tests at screening.
  • Any other co morbid psychiatric illness confirmed by MINI diagnostic scale, especially bi-polar disorder, schizophrenia or dementia.
  • Subjects with significant suicidal risk upon clinical assessment.
  • Subjects who have treatment resistant depression i.e. who have failed adequate course (daily dose and duration of treatment) of one or more antidepressants.
  • History of alcohol or drug abuse over the last 6 months.
  • History of seizures or seizure disorders.
  • Seropositive for HIV or hepatitis B (antibody or antigen).
  • Any other severe progressive and uncontrolled medical condition.
  • For controlled other medical conditions, medication to be unchanged over the 2 months preceding screening, or else the patient will be excluded.
  • Subjects with Glaucoma, Kidney Disease or Heart Disease.
  • Known hypersensitivity to mecamylamine.
  • Women of child bearing potential not taking adequate contraception and women breastfeeding.
  • Other investigational drug in previous 30 days.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00593879
TC-5231-023-CRD-003
No
Geoffrey Dunbar, VP Clinical Development & Regulatory Affairs, Targacept, Inc.
Targacept Inc.
Not Provided
Study Director: Geoffrey C Dunbar, MD Targacept Inc.
Targacept Inc.
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP